Workflow
Jasper Therapeutics, Inc. Class Action Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the JSPR Class Action Lawsuit

Core Viewpoint - A class action lawsuit has been filed against Jasper Therapeutics, Inc. for allegedly misleading investors regarding the commercial prospects of its lead product candidate, briquilimab [1][2]. Allegations - The lawsuit claims that Jasper Therapeutics failed to disclose critical information about its manufacturing controls and procedures, which could affect the clinical trial results and the commercial viability of its products [2]. - Specific allegations include the lack of necessary controls for third-party manufacturers, increasing the risk of confounded study results, and overstating the company's financial and clinical prospects [2]. Stock Price Impact - Following the revelation of these issues on July 7, 2025, Jasper's stock price plummeted by $3.73 per share, representing a 55.1% decline, closing at $3.04 per share [3]. Class Action Participation - Shareholders interested in participating as lead plaintiffs must file their papers by November 18, 2025, although participation is not required to be eligible for recovery [4]. Legal Representation - Robbins LLP operates on a contingency fee basis, meaning shareholders incur no fees or expenses unless the case is won [5].